Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Aref Al-Kali, Alfonso Quintás-Cardama, Raja Luthra, Carlos Bueso-Ramos, Sherry Pierce, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Elias Jabbour, Stefan Faderl, Farhad Ravandi, Jorges Cortes, Ayalew Tefferi, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild-type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P=0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalAmerican Journal of Hematology
Volume88
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Myelodysplastic Syndromes
Mutation
Acute Myeloid Leukemia
Leukocyte Count
Oncogenes
Retrospective Studies
Bone Marrow
Alleles
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Al-Kali, A., Quintás-Cardama, A., Luthra, R., Bueso-Ramos, C., Pierce, S., Kadia, T., ... Garcia-Manero, G. (2013). Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. American Journal of Hematology, 88(5), 365-369. https://doi.org/10.1002/ajh.23410

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. / Al-Kali, Aref; Quintás-Cardama, Alfonso; Luthra, Raja; Bueso-Ramos, Carlos; Pierce, Sherry; Kadia, Tapan; Borthakur, Gautam; Estrov, Zeev; Jabbour, Elias; Faderl, Stefan; Ravandi, Farhad; Cortes, Jorges; Tefferi, Ayalew; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: American Journal of Hematology, Vol. 88, No. 5, 05.2013, p. 365-369.

Research output: Contribution to journalArticle

Al-Kali, A, Quintás-Cardama, A, Luthra, R, Bueso-Ramos, C, Pierce, S, Kadia, T, Borthakur, G, Estrov, Z, Jabbour, E, Faderl, S, Ravandi, F, Cortes, J, Tefferi, A, Kantarjian, H & Garcia-Manero, G 2013, 'Prognostic impact of RAS mutations in patients with myelodysplastic syndrome', American Journal of Hematology, vol. 88, no. 5, pp. 365-369. https://doi.org/10.1002/ajh.23410
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. American Journal of Hematology. 2013 May;88(5):365-369. https://doi.org/10.1002/ajh.23410
Al-Kali, Aref ; Quintás-Cardama, Alfonso ; Luthra, Raja ; Bueso-Ramos, Carlos ; Pierce, Sherry ; Kadia, Tapan ; Borthakur, Gautam ; Estrov, Zeev ; Jabbour, Elias ; Faderl, Stefan ; Ravandi, Farhad ; Cortes, Jorges ; Tefferi, Ayalew ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. In: American Journal of Hematology. 2013 ; Vol. 88, No. 5. pp. 365-369.
@article{633056950701431a973092bdd0cf50b1,
title = "Prognostic impact of RAS mutations in patients with myelodysplastic syndrome",
abstract = "RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15{\%} of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4{\%} of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2{\%} of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild-type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9{\%} vs. 7{\%}) and overall survival (395 days vs. 500 days, P=0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome.",
author = "Aref Al-Kali and Alfonso Quint{\'a}s-Cardama and Raja Luthra and Carlos Bueso-Ramos and Sherry Pierce and Tapan Kadia and Gautam Borthakur and Zeev Estrov and Elias Jabbour and Stefan Faderl and Farhad Ravandi and Jorges Cortes and Ayalew Tefferi and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2013",
month = "5",
doi = "10.1002/ajh.23410",
language = "English (US)",
volume = "88",
pages = "365--369",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

AU - Al-Kali, Aref

AU - Quintás-Cardama, Alfonso

AU - Luthra, Raja

AU - Bueso-Ramos, Carlos

AU - Pierce, Sherry

AU - Kadia, Tapan

AU - Borthakur, Gautam

AU - Estrov, Zeev

AU - Jabbour, Elias

AU - Faderl, Stefan

AU - Ravandi, Farhad

AU - Cortes, Jorges

AU - Tefferi, Ayalew

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2013/5

Y1 - 2013/5

N2 - RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild-type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P=0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome.

AB - RAS is an oncogene frequently mutated in human cancer. RAS mutations have been reported in 10-15% of cases of acute myeloid leukemia (AML) but they appear to be less frequent among patients with myelodysplastic syndrome (MDS). The impact of RAS mutations in patients with MDS is unclear. We conducted a retrospective study in 1,067 patients with newly diagnosed MDS for whom RAS mutational analysis was available. Overall, 4% of patients carried mutant RAS alleles. Notably, FLT3 mutations, which were found in 2% of patients, were mutually exclusive with RAS mutations. Patients with RAS mutations had a higher white blood cell count as well as bone marrow blasts compared with patients carrying wild-type RAS. However, no differences were observed between both groups regarding the risk of AML transformation (9% vs. 7%) and overall survival (395 days vs. 500 days, P=0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome.

UR - http://www.scopus.com/inward/record.url?scp=84876723659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876723659&partnerID=8YFLogxK

U2 - 10.1002/ajh.23410

DO - 10.1002/ajh.23410

M3 - Article

C2 - 23512829

AN - SCOPUS:84876723659

VL - 88

SP - 365

EP - 369

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 5

ER -